Aurobindo Pharma aims to become debt free in 3 years sans Sandoz deal
Posted by
www.biotecnika.org
In September last year, the USD three billion drug maker said its US
subsidiary entered into an agreement to acquire commercial operations
and three manufacturing facilities in America from Sandoz Inc, USA, a
Novartis Division, for USD 900 million.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-pharma-aims-to-become-debt-free-in-3-years-sans-sandoz-deal/articleshow/72206881.cms
Subscribe to:
Post Comments (Atom)
Post a Comment